Gregory Mertz

Dr. Gregory Mertz


Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2007 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
MFMarcela Ferrés
Marcela Ferrés
PVPablo Vial
Pablo Vial
CMClaudia Marco
Claudia Marco
LYLia Yañez
Lia Yañez
PGPaula Godoy
Paula Godoy
AGAndes Virus Household Contacts Study Group
Andes Virus Household Contacts Study Group
Background. Andes virus (ANDV) infection, which has a case fatality rate of 37% in Chile, often occurs in household clusters and may be transmitted f

1 November 2004 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
GMGregory Mertz
Gregory Mertz
LMLil Miedzinski
Lil Miedzinski
DGDiane Goade
Diane Goade
APAndrew T. Pavia
Andrew T. Pavia
BHBrian Hjelle
Brian Hjelle
CGCollaborative Antiviral Study Group
Collaborative Antiviral Study Group
Background. Ribavirin is active in vitro against hantaviruses, but the findings of an open trial of the use of intravenous ribavirin for the treatmen

1 October 2006 in Current Opinion in Infectious Diseases
Verified
Journal Article
Closed access
GMGregory Mertz
Gregory Mertz
BHBrian Hjelle
Brian Hjelle
MCMark Crowley
Mark Crowley
GIGary Iwamoto
Gary Iwamoto
VTVinko Tomicic
Vinko Tomicic
PVPablo A Vial
Pablo A Vial
The purpose of this review is to summarize the current knowledge regarding the diagnosis and treatment of indigenous new world hantavirus infections. Recent studies have defined the incubation period of new world hantavirus infections, provided additional evidence for person-to-person transmission of Andes virus, described a rapid method for the presumptive diagnosis of infection in the cardiopulmonary phase through a review of the peripheral smear, and suggested that intravenous ribavirin is probably not effective for the treatment of new world hantavirus infections when started in the cardiopulmonary phase. Presumptive diagnosis may be made by a review of the peripheral blood smear after the onset of the cardiopulmonary phase. Critical care management includes the avoidance of fluid overload, pressors to maintain cardiac output, and the use of extracorporeal membrane oxygenation in the most severe cases, but treatment with intravenous ribavirin is probably not effective.

15 October 2008 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
GMGregory Mertz
Gregory Mertz
It is counterintuitive that sexual transmission of herpes simplex virus (HSV) more commonly results from contact during a short episode of asymptomatic shedding

1 October 2003 in Sexually Transmitted Diseases
Verified
Journal Article
Closed access
GMGregory Mertz
Gregory Mertz
SRSusan L. Rosenthal
Susan L. Rosenthal
LSLawrence R. Stanberry
Lawrence R. Stanberry

30 July 2019 in Viruses
Verified
Journal Article
Open access
PDF file
RLRené López
René López
CVCecilia Vial
Cecilia Vial
JGJerónimo Graf
Jerónimo Graf
MAMario Calvo Arellano
Mario Calvo Arellano
MFMarcela Ferres
Marcela Ferres
HCHantavirus Study Group in Chile
Hantavirus Study Group in Chile
Background: Hantavirus cardiopulmonary syndrome (HCPS) has a mortality up to 35–40% and its treatment is mainly supportive. A variable to predict progression from mild to severe disease is unavailable. This study was performed in patients with documented infection by Andes orthohantavirus, and the aim was to find a simple variable to predict progression to moderate/severe HCPS in patients with mild disease at admission. Methods: We performed a retrospective analysis of 175 patients between 2001 and 2018. Patients were categorized into mild, moderate, and severe disease according to organ failure and advanced support need at hospital admission (e.g., mechanical ventilation, vasopressors). Progression to moderate/severe disease was defined accordingly. Clinical and laboratory variables associated with progression were explored. Results: Forty patients with mild disease were identified; 14 of them progressed to moderate/severe disease. Only platelet count was different between those who progressed versus those that did not (37 (34–58) vs. 83 (64–177) K/mm3, p < 0.001). A ROC curve analysis showed an AUC = 0.889 (0.78–1.0) p < 0.001, with a platelet count greater than 115K /mm3 ruling out progression to moderate/severe disease. Conclusions: In patients with mild disease at presentation, platelet count could help to define priority of evacuation to tertiary care centers.